AstraZeneca’s, Bydureon, has met its endpoint in a phase 3 clinical trial of people aged 10 to 17 with type 2 diabetes. The study is testing a once-weekly formulation of the glucagon-like peptide-1 receptor agonist exenatide.
Click here to read the entire article.